Modality
siRNA
MOA
BCL-2i
Target
FXIa
Pathway
Fibrosis
FLDravet
Development Pipeline
Preclinical
Apr 2018
→ Jun 2026
PreclinicalCurrent
NCT08855956
1,529 pts·Dravet
2018-04→2026-06·Not yet recruiting
1,529 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-06-022mo awayInterim· Dravet
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
Preclinical
Not yet…
Catalysts
Interim
2026-06-02 · 2mo away
Dravet
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08855956 | Preclinical | Dravet | Not yet recr... | 1529 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa |